Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Abou-Alfa, GK; Lau, G; Kudo, M; Chan, SL; Kelley, RK; Furuse, J; Sukeepaisarnjaroen, W; Kang, YK; Dao, TV; De Toni, EN; Rimassa, L; Breder, V; Vasilyev, A; Heurgue, A; Tam, VC; Mody, K; Thungappa, SC; Ostapenko, Y; Yau, T; Azevedo, S; Varela, M; Cheng, AL; Qin, SK; Galle, PR; Ali, S; Gupta, C; Makowsky, M; Kurland, JF; Negro, A; Sangro, B

Abou-Alfa, GK (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.

FUTURE ONCOLOGY, 2023; 19 (38): 2505

Abstract

What is this summary about?This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索